Loading organizations...
Loading organizations...
OpGen is a technology company.
OpGen develops and commercializes molecular diagnostic solutions designed to combat infectious diseases. The company provides a suite of advanced diagnostics, including rapid PCR-based panels and next-generation sequencing (NGS) services, which offer precise identification and characterization of pathogens. Their approach harnesses the power of molecular diagnostics to deliver actionable insights, aiming to improve patient management and public health outcomes.
The company was founded in 2002 by David Schwartz in Rockville, Maryland. Schwartz established OpGen with the understanding that conventional diagnostic methods for infectious diseases often lacked the speed and specificity required for effective intervention. This insight drove the creation of a company focused on bringing advanced molecular technologies to the forefront of clinical microbiology.
OpGen’s products primarily serve healthcare providers, hospitals, and clinical laboratories striving for more accurate and timely diagnoses of infections. The company envisions a future where its diagnostic platforms contribute significantly to curbing the global threat of antimicrobial resistance and improving the standard of care for patients suffering from infectious diseases.
OpGen has raised $81.0M across 5 funding rounds.
OpGen has raised $81.0M in total across 5 funding rounds.
OpGen, Inc. is a Gaithersburg, MD-based precision medicine company originally focused on molecular diagnostics and bioinformatics to combat infectious diseases, particularly antimicrobial resistance (AMR).[1][2] It develops products like the Unyvero system, Acuitas AMR Gene Panel, Acuitas Lighthouse, and the ARES Technology Platform, which use NGS technology and AI-powered bioinformatics for rapid pathogen identification, antibiotic response prediction, and guiding therapy to improve patient outcomes and reduce multidrug-resistant organism (MDRO) spread.[1][2] Recently, OpGen underwent a strategic transformation, pivoting through its subsidiary CapForce to digital investment banking and financial technology, sponsoring capital market listings for growth-stage firms (market caps $1-10B) and developing a platform for cross-border securities trading, AI-driven robo-advisory, and FinTech cap table management.[1][3] This shift addresses Nasdaq compliance issues, including a 1-for-10 reverse stock split in May 2024 and delayed filings.[1]
The company serves clinicians, hospitals, and labs worldwide, solving critical problems in infectious disease management and now extending to fintech services for mid-sized private companies seeking public listings.[1][2][3]
Founded prior to its public prominence, OpGen started as a provider of "optical mapping" services for bacterial strain identification in laboratories globally, leveraging molecular microbiology.[4] It evolved into a precision diagnostics leader with subsidiaries Curetis GmbH and Ares Genetics GmbH, expanding into multiplexed panels like Unyvero for syndromic testing.[1][2] Key early traction came from addressing AMR threats through rapid molecular diagnostics.[1]
A pivotal shift occurred recently with the formation of CapForce International Holdings Ltd., repositioning OpGen toward digital investment banking amid operational challenges, including Nasdaq notices in 2024.[1][3] CEO Oliver Schacht has been central, appearing in videos discussing the combined company and future diagnostics.[1]
OpGen rides the AMR crisis trend, where molecular diagnostics are essential amid rising drug-resistant infections, aligning with precision medicine demands in healthcare.[1][2] Its timing leverages post-pandemic focus on rapid testing, while the CapForce pivot taps booming fintech for IPO sponsorships amid volatile public markets favoring mid-cap growth firms.[3]
Market forces like regulatory pressures on antibiotics and digital banking deregulation favor its dual expertise in biotech and AI-driven finance.[1][3] OpGen influences ecosystems by bridging diagnostics innovation with capital access, potentially accelerating AMR solutions and public listings for tech-enabled companies.[2][3]
OpGen's diagnostics legacy positions it to capitalize on AMR diagnostics growth, but success hinges on CapForce's platform launch amid Nasdaq hurdles.[1][3] Trends like AI in healthcare/bioinformatics and robo-advisory in fintech will shape its path, potentially evolving it into a hybrid medtech-fintech player.
Watch for platform rollout and filing compliance; strong execution could restore investor confidence, tying back to its core mission of transforming patient care and growth-stage financing through cutting-edge tech.[1][3]
OpGen has raised $81.0M in total across 5 funding rounds.
OpGen's investors include Merck, CHL Medical Partners, Cross Creek Advisors, Misti Ushio, Highland Capital Partners, Evan Jones, Versant Ventures, 5AM Ventures, Mason Wells Biomedical.
OpGen has raised $81.0M across 5 funding rounds. Most recently, it raised $6.0M Other Equity in July 2015.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 15, 2015 | $6.0M Other Equity | Merck | |
| Mar 7, 2012 | $17.0M Other Equity | CHL Medical Partners, Cross Creek Advisors, Misti Ushio, Highland Capital Partners, Evan Jones, Versant Ventures | |
| Mar 1, 2012 | $17.0M Series C | 5AM Ventures, Highland Capital Partners, Versant Ventures | |
| Sep 1, 2010 | $17.0M Series B | Evan Jones | 5AM Ventures, Highland Capital Partners, Versant Ventures, CHL Medical Partners, Mason Wells Biomedical |
| Sep 1, 2007 | $24.0M Venture Round | 5AM Ventures, Highland Capital Partners, Versant Ventures |